Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound MEDLINE
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(Thyroid Cancer)
76,186 results
  • RADIATION PROTECTION IN THE RELEASE OF PATIENTS RECEIVING 131I TREATMENT. [Journal Article]
    Radiat Prot Dosimetry 2019Mattar E, Salih MA, … Suliman II
  • Radiation measurements were made to support radiation protection decisions and instructions concerning the release of patients receiving 131I treatment in Sudan. In hyperthyroidism, administered activity ranged from 370 to 1110 MBq (average: 817.8 MBq), and air-absorbed dose rate at 1 m in front of the patients varied from 20 to 66 μGy h-1 (average: 47.0 μGy h-1). For thyroid cancer patients, the…
  • ACR TI-RADS: Pitfalls, Solutions, and Future Directions. [Journal Article]
    Radiographics 2019; :190026Tappouni RR, Itri JN, … Ou JJ
  • The high prevalence of thyroid nodules combined with the generally indolent growth of thyroid cancer present a challenge for optimal patient care. Risk classification models based on US features have been created by multiple professional societies, including the American College of Radiology (ACR), which published the Thyroid Imaging Reporting and Data System (TI-RADS) in 2017. ACR TI-RADS uses a…
  • Orbital Radioiodine Uptake on Scintigraphy in a Patient with Thyroid Cancer. [Journal Article]
    Eur Thyroid J 2019; 8(4):221-224García-Moreno RM, Escabias C, … Lecumberri B
  • Orbital radioiodine uptake in patients with thyroid cancer is very uncommon with only a few reported cases, most of them being metastasis. The accumulation of 131I in nonthyroidal tissues and body fluids can lead to false-positive results in scintigraphy, which are sometimes difficult to differentiate from true metastases.
New Search Next